Monday, April 20, 2026 – Audience: Health Care Professional, Consumer January 13, 2026
FDA Evaluation Did Not Identify an Increased Risk of Suicidal Ideation or Behavior With the Use of GLP-1 RA Medications
This information is an update to the FDA Drug Safety...
Monday, April 20, 2026 – Popular weight-loss drugs like Ozempic and Wegovy can dramatically curb appetite, but experts warn many users are flying blind when it comes to nutrition. New research suggests people taking these medications may not be getting enough guidance on protein, vitamins, and overall diet quality, increasing the risk of muscle loss and nutrient deficiencies.
Monday, April 20, 2026 – Could weight-loss drugs shrink the body representation we’ve spent decades seeking?
Monday, April 20, 2026 – INDIANAPOLIS, March 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational...
Monday, April 20, 2026 – INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide)...
Monday, April 20, 2026 – (MedPage Today) -- A 6-month hiatus in GLP-1 drug use was linked with an increased risk of major adverse cardiovascular events in patients with type 2 diabetes compared with continued use, according to a target trial emulation. (BMJ Medicine)...
Monday, April 20, 2026 – PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers...
Monday, April 20, 2026 – (MedPage Today) -- GLP-1 medications showed a range of potential benefits and safety concerns in an umbrella review of non-cardiometabolic outcomes, though the data quality for many remained limited.
Across 60 meta-analyses that assessed 116 non...
Monday, April 20, 2026 – Eli Lilly and Co. anticipates shipping newly approved Foundayo (orforglipron) within the next week, as the drug becomes the second oral weight-loss glucagon-like peptide-1 (GLP-1) receptor agonist to enter the U.S. market following December’s approval of Novo Nordisk A/S’ Wegovy (semaglutide) pill.
Monday, April 20, 2026 – (MedPage Today) -- The FDA has approved a second oral GLP-1 receptor agonist for weight loss in adults with obesity or overweight and weight-related comorbidities.
A once-daily tablet, orforglipron (Foundayo) is indicated in conjunction with a...